PROGRAMME
Check this page regularly for updates
WEDNESDAY 23 MARCH - EDUCATION SESSION
Educational Session for PhD Students, MD Students and MD PhD Students
Venue: Herrenhausen Palace
09:00-10:40
Education Session 1
Chairs: Toni Cathomen, Axel Schambach, Hildegard Büning
09:00-09:10 Toni Cathomen, President DG-GT - University of Freiburg, Axel Schambach, President Elect DG-GT - Hannover Medical School; Hildegard Büning, Scientific Secretary DG-GT - Hannover Medical School
Welcome address
09:10-09:40 Hildegard Büning, Hannover Medical School ⓘ
Optimizing delivery tools for gene therapy (AAV/LV/Nonviral)
09:40-10:10 Axel Schambach, Hannover Medical School ⓘ
Exploiting stem cells for combined gene and cell therapies
10:10-10:40 Toni Cathomen, University of Freiburg ⓘ
Designer nucleases: Basics, challenges and beyond
10:40-11:00
Break
WEDNESDAY 23 MARCH
Venue: Herrenhausen Palace
12:00-13:30
Registration
13:30-14:00
Opening Ceremony
Toni Cathomen, University of Freiburg & President DG-GT; Axel Schambach, Hannover Medical School & President-elect DG-GT; Hildegard Büning, Hannover Medical School & Scientific Secretrary DG-GT; Michael Manns, President of Hannover Medical School; Selahattin Danisman, Program Director, Volkswagen Foundation
14:00-16:15
Session 1: Optimizing the vector world and modeling systems – Part A
Chairs: Hildegard Büning, Hannover Medical School; Axel Schambach, Hannover Medical School
14:00-14:15 Hildegard Büning, Hannover Medical School; Axel Schambach, Hannover Medical School
Optimizing the vector world – current status in a nutshell
14:15-14:45 Els Verhoeyen, University of Nice, ENS Lyon ⓘ
INV01: Novel lentiviral pseudotypes for T and NK cell gene therapy and ‘nanoblades’ for efficient gene editing in hematopoietic gene therapy target cells.
14:45-15:15 Leszek Lisowski, University of Sydney
INV02: Canonical AAV gene therapy and clinical gene editing: capsid evolution and translational vectorology
15:15-15:45 Joel Rurik, University of Pennsylvania ⓘ
INV03: CAR T cells produced in vivo to treat cardiac injury
15:45-16:00 Rajendra Khanal, Hannover Medical School
OR01: mRNA-based therapies for liver diseases: HNF4A mRNA administration via lipid nanoparticles miti
gates liver fibrosis in preclinical models
16:00-16:15 Zoltan Ivics, Paul Ehrlich Institute, Langen
OR02: Engineered Sleeping Beauty transposase redirects transposon integration away from genes
16:15-16:45
Break
16:45-19:15
Session 2: Optimizing the vector world and modeling systems – Part B
Chairs: Christian Kupatt, Technische Universität München; Michael Ott, Hannover Medical School
16:45-17:00 Christian Kupatt, Technische Universität München, Michael Ott, Hannover Medical School
Optimizing genetic payload and modeling systems – current status in a nutshell
17:00-17:45 Luigi Naldini, SR Tiget, Milan ⓘ
INV04: Hematopoietic stem cell gene therapy: how to choose the best tools and broaden its therapeutic scope
17:45-18:15 Alberto Auricchio, Tigem Naples ⓘ
INV05: Expanding AAV transfer capacity on the retina
18:15-18:45 Cornelia Lee-Thedieck, Leibniz University Hannover ⓘ
INV06: In vitro models of the hematopoietic stem cell niche: from fundamental research to application as test systems
18:45-19:00 Reto Eggenschwiler, Hannover Medical School
OR03: PB-PE, a piggyBac prime editing platform for efficient evaluation of optimal CRISPR-PE designs
19:00-19:15 Dawid Glow, University Medical Center Hamburg-Eppendorf
OR04: CRISPR-to-Kill (C2K) - development of a versatile method that utilizes the bacterial immune system to kill cancer cells
19:15 -19:30
Break
19:30-20:15
Keynote 1: Wolfram Ostertag Lecture
Chair: Christopher Baum, Charité, Berlin Institute of Health ; Carol Stocking, University Medical Center Hamburg - Eppendorf
19:30-20:15 Rudolf Jaenisch, Whitehead Institute, MIT, Boston
INV07: Genomic integration of SARS-CoV-2 sequences and potential relevance for COVID-19
20:15
Dinner Reception
THURSDAY 24 MARCH
08:00-09:00
Registration
09:00-11:15
Session 3: iPSC- and stem cell-based cell therapies
Chairs: Thomas Moritz, Hannover Medical School; Tobias Cantz, Hannover Medical School
09:00-09:15 Thomas Moritz, Hannover Medical School; Tobias Cantz, Hannover Medical School
iPSC and stem cell-based therapies – current status in a nutshell
09:15-09:45 Ulrich Martin, Hannover Medical School ⓘ
INV08: hiPS cells for clinical heart repair: Generation of GMP-compliant cell lines, large scale cardiomyocyte production and preclinical evaluation in a non-human primate model
09:45-10:15 Miguel Esteban, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
INV09: Single stem cells
10:15-10:45 Claire Booth, University College London ⓘ
INV10: Stem cell gene therapy for immune deficiencies; new approaches to correction
10:45-11:00 Daniela Paasch, Hannover Medical School
OR05: A universal platform to generate chimeric antigen receptor macrophages from human stem cell sources
11:00-11:15 Masako Monica Kaufmann, Medical Center – University of Freiburg
OR06: Universal CAST-Seq: Target sequence-independent detection of CRISPR-Cas off-target effects in primary human stem cells
11:15-11:45
Break
11:45-13:00
Session 4: Manfred Schmidt Memorial Session
Chairs: Christof von Kalle, Charité, Berlin Institute of Health
11:45-12:00 Christof von Kalle, Charité, Berlin Institute of Health
Introduction
12:00-12:30 Alain Fischer, Necker-Enfants Malades Hospital, Paris ⓘ
INV11: Long term analysis of gene therapy for SCID and related diseases
12:30-13:00 David Williams, Harvard Medical School, Boston ⓘ
INV12: Flipping the switch; post-transcriptional genetic silencing of BCL11A to treat Sickle Cell Disease
13:00-14:00
Lunch
14:00-16:00
Session 5: Evolving topics in gene and cell therapy, including zoonoses and infectious diseases
Chairs: Boris Fehse, University of Hamburg; Christine Falk, Hannover Medical School
14:00-14:15 Boris Fehse, University of Hamburg; Christine Falk, Hannover Medical School
Evolving topics in gene and cell therapy – current status in a nutshell
14:15-14:45 Stefan Pöhlmann, DPFZ, Göttingen ⓘ
INV13: Coronavirus entry into cells
14:45-15:15 Axel Schambach, Hannover Medical School; Ulrich Kalinke, TWINCORE, Hannover
INV14: Preventive strategies for current and future pandemics – a Hannover perspective
15:15-15:45 Hinrich Staecker, University of Kansas ⓘ
INV15: Vectorization approaches for different human inner ear diseases: Regeneration, protection and treatment of genetic disorders
15:45-16:00 Lea Krutzke, University of Ulm
OR07: Process-related impurities in the ChAdOx1 nCov-19 vaccine
16:00-16:30
Break
16:30-18:45
Session 6: Novel approaches in cancer therapy
Chairs: Dirk Nettelbeck, DKFZ, Heidelberg; Michael Morgan, Hannover Medical School
16:30 - 16:45 Dirk Nettelbeck,DKFZ, Heidelberg, Michael Morgan, Hannover Medical School
Novel approaches in cancer therapy – current status in a nutshell
16:45-17:15 Guy Ungerechts, NCT Heidelberg ⓘ
INV16: Immunovirotherapy for Cancer
17:15-17:45 Benjamin Rengstl, BionNTech, Mainz ⓘ
INV17: BNT211: A Phase I trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumors
17:45-18:15 Martin Sauer, Hannover Medical School ⓘ
INV18: Off the shelf cellular immunotherapy: Dream or Necessity?
18:15-18:30 Ulrike Naumann, University of Tübingen
OR08: Immunogenic cell death determines the therapeutic impact of the oncolytic adenovirus XVir-N-31 in glioma and induces abscopal effects in combination with immune checkpoint inhibition
18:30-18:45 Maria Silvia Roman Azcona, Medical Center – University of Freiburg
OR09: Sustained modulation of immune checkpoint expression in CAR T cells upon transient exposure to a designer epigenome modifier
18:45-19:00
Break
19:00-19:45
Keynote 2: Making gene therapy a clinical reality
Chairs: Hinrich Abken, Regensburg Center for Interventional Immunology
19:00-19:45 Carl June, University of Pennsylvania ⓘ
INV19: Updates with CAR T
FRIDAY 25 MARCH
08:30-09:00
Registration
09:00-11:15
Session 7: Genome and epigenome editing: On the road towards the clinic
Chairs: Claudio Mussolino, University of Freiburg; Julian Grünewald, Technische Universität München
09:00-09:15 Claudio Mussolino, University of Freiburg; Julian Grünewald, Technische Universität München
Genome and epigenome editing – current status in a nutshell
09:15-09:45 Toni Cathomen, University of Freiburg ⓘ
INV20: On- and off-target effects of gene editing tools in human stem cells
09:45-10:15 Virgis Siksnys, Vilnius University ⓘ
INV21: Novel CRISPR-Cas nucleases as potential genome editing tools?
10:15-10:45 Frank Buchholz, TU Dresden ⓘ
INV22: Genome Editing with Designer-Recombinases
10:45-11:00 Viviane Dettmer-Monaco, Medical Center- University of Freiburg
OR10: Gene editing of hematopoietic stem cells restores the cytotoxic T cell response in a murine model of familial hemophagocytic lymphohistiocytosis type 3
11:00-11:15 Adrian Schwarzer, Hannover Medical School
OR11: A four-color AAV6 system for efficient biallelic homology-directed genome editing (HDR) without AAV vector integration into CRISPR-Cas9 induced double-strand breaks
11:15-13:00
Poster Walk & Lunch
13:00-15:30
Session 8: Clinical translation of gene and cell therapies
Chairs: Stefan Kochanek, Uniklinik Ulm; Ulrike Köhl, Fraunhofer IZI, Leipzig
13:00-13:15 Stefan Kochanek, Uniklinik Ulm, Ulrike Köhl, Fraunhofer IZI, Leipzig
Clinical translation of gene and cell therapies – current status in a nutshell
13:15-13:45 Frank Staal, Leiden University ⓘ
INV23: Gene Therapy for Recombinase-Activating Gene-1-Deficient SCID
13:45-14:15 Thomas Thum, Hannover Medical School ⓘ
INV24: (Pre)clinical development of noncoding RNA based therapeutics
14:15-14:45 Fatima Bosch, Universitat Autònoma de Barcelona ⓘ
INV25: Gene therapy for the Mature Onset Diabetes of the Young Type 3 (MODY3)
14:45-15:00 Tobias Bexte, Goethe University Frankfurt
OR12: High antileukemic efficiency of CD19-CAR NK cells engineered with Sleeping Beauty transposon vectors
15:00-15:15 Karl Petri, Massachusetts General Hospital, Harvard Medical School, Boston
OR13: Global-scale CRISPR gene editor specificity profiling by ONE-seq identifies population-specific, variant off-target effects.
15:15-15:30 Lea-Isabell Schwarze University Medical Center Hamburg-Eppendorf
OR14: CCR5-edited CAR T cells for the treatment of HIV-positive cancer patients
15:30-16:00
Session 9: Ethical considerations and challenges for the future
Chairs: Toni Cathomen, University of Freiburg; Zoltan Ivics, Paul Ehrlich Institute, Langen
16:00
Closing, Prizes & Awards
Chair: Hildegard Büning, Hannover Medical School